{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T23:39:50Z","timestamp":1785886790277,"version":"3.56.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T00:00:00Z","timestamp":1658966400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T00:00:00Z","timestamp":1658966400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","award":["HI14C1277"],"award-info":[{"award-number":["HI14C1277"]}],"id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>There is limited information regarding disease-modifying antirheumatic drug (DMARD)-dependent risks of overall, incident, and recurrent herpes zoster (HZ) during first-line biologic DMARD (bDMARD) or targeted synthetic DMARD (tsDMARD) treatment among patients with seropositive rheumatoid arthritis (RA) in terms of HZ risk.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A total of 11,720 patients with seropositive RA who were prescribed bDMARD or tofacitinib between January 2011 and January 2019 from the Korean Health Insurance Review &amp; Assessment Service database were studied. A multivariate Cox proportional hazards regression model was adopted to evaluate the adjusted hazard ratio (aHR) with 95% confidence interval (CI) for the risk of HZ dependent on the choice of first-line bDMARDs or tsDMARD, including etanercept, infliximab, adalimumab, golimumab, tocilizumab, rituximab, tofacitinib, and abatacept.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>During the 34,702 person-years of follow-up, 1686 cases (14.4%) of HZ were identified, including 1372 (11.7%) incident and 314 (2.7%) recurrent HZs. Compared with that of the abatacept group, tofacitinib increased the overall risk (aHR, 2.46; 95% CI, 1.61\u20133.76; <jats:italic>P<\/jats:italic>&lt;0.001), incidence (aHR, 1.99; 95% CI, 1.18\u20133.37; <jats:italic>P<\/jats:italic>=0.011), and recurrence (aHR, 3.69; 95% CI, 1.77\u20137.69; <jats:italic>P<\/jats:italic>&lt;0.001) of HZ. Infliximab (aHR, 1.36; 95% CI, 1.06\u20131.74; <jats:italic>P<\/jats:italic>=0.017) and adalimumab (aHR, 1.29; 95% CI, 1.02\u20131.64; <jats:italic>P<\/jats:italic>=0.032) also increased the overall HZ risk. Moreover, a history of HZ was found to be an independent risk factor for HZ (aHR, 1.54; 95% CI, 1.33\u20131.78; <jats:italic>P<\/jats:italic>&lt;0.001).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>HZ risk is significantly increased in RA patients with a history of HZ after the initiation of bDMARDs or tsDMARD. The risk of incident and recurrent HZ was higher after tofacitinib treatment in patients with RA than that after treatment with bDMARDs. Individualized characteristics and history of HZ should be considered when selecting bDMARDs or tsDMARD for RA patients considering HZ risks.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13075-022-02871-1","type":"journal-article","created":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T06:02:41Z","timestamp":1658988161000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Incident and recurrent herpes zoster for first-line bDMARD and tsDMARD users in seropositive rheumatoid arthritis patients: a nationwide cohort study"],"prefix":"10.1186","volume":"24","author":[{"given":"Seogsong","family":"Jeong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seulggie","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Min","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinseok","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byeongzu","family":"Ghang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6975-8627","authenticated-orcid":false,"given":"Eun Young","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,28]]},"reference":[{"issue":"11","key":"2871_CR1","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1136\/annrheumdis-2019-215920","volume":"78","author":"S Safiri","year":"2019","unstructured":"Safiri S, Kolahi AA, Hoy D, et al. Global, regional and national burden of rheumatoid arthritis 1990\u20132017: a systematic analysis of the Global Burden of Disease study 2017. Ann Rheum Dis. 2019;78(11):1463\u201371.","journal-title":"Ann Rheum Dis."},{"issue":"6","key":"2871_CR2","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1136\/annrheumdis-2019-216656","volume":"79","author":"A Kerschbaumer","year":"2020","unstructured":"Kerschbaumer A, Sepriano A, Smolen JS, et al. Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis. 2020;79(6):744\u201359.","journal-title":"Ann Rheum Dis."},{"issue":"6","key":"2871_CR3","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","volume":"76","author":"JS Smolen","year":"2017","unstructured":"Smolen JS, Landew\u00e9 R, Bijlsma J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease\u2013modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017;76(6):960\u201377.","journal-title":"Ann Rheum Dis."},{"issue":"1","key":"2871_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/art.39480","volume":"68","author":"JA Singh","year":"2016","unstructured":"Singh JA, Saag KG, Bridges SL Jr, et al. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheumatol. 2016;68(1):1\u201326.","journal-title":"Arthritis Rheumatol."},{"issue":"2","key":"2871_CR5","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.semarthrit.2014.05.001","volume":"44","author":"F Matcham","year":"2014","unstructured":"Matcham F, Scott IC, Rayner L, et al. The impact of rheumatoid arthritis on quality\u2013of\u2013life assessed using the SF\u201336: a systematic review and meta\u2013analysis. Semin Arthritis Rheum. 2014;44(2):123\u201330.","journal-title":"Semin Arthritis Rheum."},{"issue":"5","key":"2871_CR6","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1136\/ard.2010.128637","volume":"70","author":"K Au","year":"2011","unstructured":"Au K, Reed G, Curtis JR, et al. High disease activity is associated with an increased risk of infection in patients with rheumatoid arthritis. Ann Rheum Dis. 2011;70(5):785\u201391.","journal-title":"Ann Rheum Dis."},{"key":"2871_CR7","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k1036","volume":"361","author":"BR England","year":"2018","unstructured":"England BR, Thiele GM, Anderson DR, Mikuls TR. Increased cardiovascular risk in rheumatoid arthritis: mechanisms and implications. BMJ. 2018;361:k1036.","journal-title":"BMJ."},{"issue":"1","key":"2871_CR8","doi-asserted-by":"publisher","first-page":"ITC1","DOI":"10.7326\/AITC201901010","volume":"170","author":"JA Sparks","year":"2019","unstructured":"Sparks JA. Rheumatoid Arthritis. Ann Intern Med. 2019;170(1):ITC1\u2013ITC16.","journal-title":"Ann Intern Med."},{"issue":"9","key":"2871_CR9","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.1002\/art.39670","volume":"68","author":"H Yun","year":"2016","unstructured":"Yun H, Yang S, Chen L, et al. Risk of herpes zoster in autoimmune and inflammatory diseases: implications for vaccination. Arthritis Rheumatol. 2016;68(9):2328\u201337.","journal-title":"Arthritis Rheumatol."},{"issue":"8","key":"2871_CR10","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1002\/art.23112","volume":"57","author":"AL Smitten","year":"2007","unstructured":"Smitten AL, Choi HK, Hochberg MC, et al. The risk of herpes zoster in patients with rheumatoid arthritis in the United States and the United Kingdom. Arthritis Rheum. 2007;57(8):1431\u20138.","journal-title":"Arthritis Rheum."},{"issue":"7","key":"2871_CR11","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1001\/jama.2009.146","volume":"301","author":"A Strangfeld","year":"2009","unstructured":"Strangfeld A, Listing J, Herzer P, et al. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti\u2013TNF\u2013alpha agents. JAMA. 2009;301(7):737\u201344.","journal-title":"JAMA."},{"issue":"9","key":"2871_CR12","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1111\/1756-185X.13300","volume":"21","author":"R Sakai","year":"2018","unstructured":"Sakai R, Kasai S, Hirano F, et al. No increased risk of herpes zoster in TNF inhibitor and non\u2013TNF inhibitor users with rheumatoid arthritis: epidemiological study using the Japanese health insurance database. Int J Rheum Dis. 2018;21(9):1670\u20137.","journal-title":"Int J Rheum Dis."},{"issue":"4","key":"2871_CR13","first-page":"ofw205","volume":"3","author":"F Marra","year":"2016","unstructured":"Marra F, Lo E, Kalashnikov V, Richardson K. Risk of herpes zoster in individuals on biologics, disease\u2013modifying antirheumatic drugs, and\/or corticosteroids for autoimmune diseases: a systematic review and meta\u2013analysis. Open Forum. Infect Dis. 2016;3(4):ofw205.","journal-title":"Infect Dis."},{"issue":"10","key":"2871_CR14","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1136\/annrheumdis-2016-209131","volume":"75","author":"JR Curtis","year":"2016","unstructured":"Curtis JR, Xie F, Yun H, Bernatsky S, Winthrop KL. Real\u2013world comparative risks of herpes virus infections in tofacitinib and biologic\u2013treated patients with rheumatoid arthritis. Ann Rheum Dis. 2016;75(10):1843\u20137.","journal-title":"Ann Rheum Dis."},{"issue":"2","key":"2871_CR15","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.jacc.2017.05.015","volume":"70","author":"MC Kim","year":"2017","unstructured":"Kim MC, Yun SC, Lee HB, et al. Herpes zoster increases the risk of stroke and myocardial infarction. J Am Coll Cardiol. 2017;70(2):295\u20136.","journal-title":"J Am Coll Cardiol."},{"issue":"4","key":"2871_CR16","doi-asserted-by":"publisher","first-page":"547","DOI":"10.3390\/jcm8040547","volume":"8","author":"PH Wu","year":"2019","unstructured":"Wu PH, Chuang YS, Lin YT. Does herpes zoster increase the risk of stroke and myocardial infarction? A comprehensive review. J Clin Med. 2019;8(4):547.","journal-title":"J Clin Med."},{"issue":"3","key":"2871_CR17","first-page":"799","volume":"46","author":"S Cheol Seong","year":"2017","unstructured":"Cheol Seong S, Kim YY, Khang YH, et al. Data Resource Profile: The National Health Information Database of the National Health Insurance Service in South Korea. Int J Epidemiol. 2017;46(3):799\u2013800.","journal-title":"Int J Epidemiol."},{"key":"2871_CR18","doi-asserted-by":"publisher","DOI":"10.4178\/epih\/e2014008","volume":"36","author":"L Kim","year":"2014","unstructured":"Kim L, Kim JA, Kim S. A guide for the utilization of Health Insurance Review and Assessment Service national patient samples. Epidemiol Health. 2014;36:e2014008.","journal-title":"Epidemiol Health."},{"issue":"3","key":"2871_CR19","doi-asserted-by":"publisher","first-page":"146","DOI":"10.4082\/kjfm.20.0062","volume":"41","author":"S Kim","year":"2020","unstructured":"Kim S, Kim MS, You SH, Jung SY. Conducting and Reporting a Clinical Research Using Korean Healthcare Claims Database. Korean J Fam Med. 2020;41(3):146\u201352.","journal-title":"Korean J Fam Med."},{"issue":"12","key":"2871_CR20","doi-asserted-by":"publisher","first-page":"2985","DOI":"10.1007\/s00296-013-2833-x","volume":"33","author":"SK Cho","year":"2013","unstructured":"Cho SK, Sung YK, Choi CB, Kwon JM, Lee EK, Bae SC. Development of an algorithm for identifying rheumatoid arthritis in the Korean National Health Insurance claims database. Rheumatol Int. 2013;33(12):2985\u201392.","journal-title":"Rheumatol Int."},{"issue":"4","key":"2871_CR21","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.semarthrit.2021.06.002","volume":"51","author":"S Choi","year":"2021","unstructured":"Choi S, Ghang B, Jeong S, et al. Association of first, second, and third-line bDMARDs and tsDMARD with drug survival among seropositive rheumatoid arthritis patients: cohort study in a real world setting. Semin Arthritis Rheum. 2021;51(4):685\u201391.","journal-title":"Semin Arthritis Rheum."},{"key":"2871_CR22","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s13223-020-00453-x","volume":"16","author":"SY Kim","year":"2020","unstructured":"Kim SY, Oh DJ, Choi HG. Asthma increases the risk of herpes zoster: a nested case\u2013control study using a national sample cohort. Allergy Asthma Clin Immunol. 2020;16:52.","journal-title":"Allergy Asthma Clin Immunol."},{"issue":"3","key":"2871_CR23","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.jbspin.2013.07.009","volume":"81","author":"H Che","year":"2014","unstructured":"Che H, Lukas C, Morel J, Combe B. Risk of herpes\/herpes zoster during anti\u2013tumor necrosis factor therapy in patients with rheumatoid arthritis. Systematic review and meta\u2013analysis. Joint Bone Spine. 2014;81(3):215\u201321.","journal-title":"Joint Bone Spine."},{"issue":"9","key":"2871_CR24","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1001\/jama.2013.1099","volume":"309","author":"KL Winthrop","year":"2013","unstructured":"Winthrop KL, Baddley JW, Chen L, et al. Association between the initiation of anti\u2013tumor necrosis factor therapy and the risk of herpes zoster. JAMA. 2013;309(9):887\u201395.","journal-title":"JAMA."},{"issue":"1","key":"2871_CR25","doi-asserted-by":"publisher","first-page":"ofx007","DOI":"10.1093\/ofid\/ofx007","volume":"4","author":"K Shiraki","year":"2017","unstructured":"Shiraki K, Toyama N, Daikoku T, Yajima M. Miyazaki Dermatologist Society. Herpes Zoster and Recurrent Herpes Zoster. Open Forum Infect Dis. 2017;4(1):ofx007.","journal-title":"Open Forum Infect Dis"},{"issue":"2","key":"2871_CR26","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2019.34.e1","volume":"34","author":"YJ Kim","year":"2018","unstructured":"Kim YJ, Lee CN, Lee MS, et al. Recurrence rate of herpes zoster and its risk factors: a population-based cohort study. J Korean Med Sci. 2018;34(2):e1.","journal-title":"J Korean Med Sci."},{"issue":"5","key":"2871_CR27","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1002\/acr.22470","volume":"67","author":"H Yun","year":"2015","unstructured":"Yun H, Xie F, Delzell E, et al. Risks of herpes zoster in patients with rheumatoid arthritis according to biologic disease\u2013modifying therapy. Arthritis Care Res (Hoboken). 2015;67(5):731\u20136.","journal-title":"Arthritis Care Res (Hoboken)."},{"issue":"9","key":"2871_CR28","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1086\/379048","volume":"188","author":"MJ Levin","year":"2003","unstructured":"Levin MJ, Smith JG, Kaufhold RM, et al. Decline in varicella\u2013zoster virus (VZV)\u2013specific cell\u2013mediated immunity with increasing age and boosting with a high\u2013dose VZV vaccine. J Infect Dis. 2003;188(9):1336\u201344.","journal-title":"J Infect Dis."},{"issue":"1","key":"2871_CR29","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1186\/s13075-018-1742-5","volume":"20","author":"D Schub","year":"2018","unstructured":"Schub D, Assmann G, Sester U, Sester M, Schmidt T. VZV\u2013specific T\u2013cell levels in patients with rheumatic diseases are reduced and differentially influenced by antirheumatic drugs. Arthritis Res Ther. 2018;20(1):252.","journal-title":"Arthritis Res Ther."},{"issue":"6","key":"2871_CR30","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1002\/art.34329","volume":"64","author":"K Maeshima","year":"2012","unstructured":"Maeshima K, Yamaoka K, Kubo S, et al. The JAK inhibitor tofacitinib regulates synovitis through inhibition of interferon\u2013\u03b3 and interleukin\u201317 production by human CD4+ T cells. Arthritis Rheum. 2012;64(6):1790\u20138.","journal-title":"Arthritis Rheum."},{"issue":"8","key":"2871_CR31","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1089\/1079990041689665","volume":"24","author":"L Malmgaard","year":"2004","unstructured":"Malmgaard L. Induction and regulation of IFNs during viral infections. J Interferon Cytokine Res. 2004;24(8):439\u201354.","journal-title":"J Interferon Cytokine Res."},{"issue":"7","key":"2871_CR32","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.3109\/10428194.2014.969260","volume":"56","author":"CW Jung","year":"2015","unstructured":"Jung CW, Shih LY, Xiao Z, et al. Efficacy and safety of ruxolitinib in Asian patients with myelofibrosis. Leuk Lymphoma. 2015;56(7):2067\u201374.","journal-title":"Leuk Lymphoma."},{"issue":"6","key":"2871_CR33","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/j.mayocp.2018.02.017","volume":"93","author":"R Harpaz","year":"2018","unstructured":"Harpaz R, Dahl RM. Administrative data to explore the role of family history as a risk factor for herpes zoster. Mayo Clin Proc. 2018;93(6):747\u201351.","journal-title":"Mayo Clin Proc."},{"issue":"4","key":"2871_CR34","first-page":"ofw184","volume":"3","author":"RT Levinson","year":"2016","unstructured":"Levinson RT, Hulgan T, Kalams SA, Fessel JP, Samuels DC. Mitochondrial haplogroups as a risk factor for herpes zoster. Open Forum. Infect Dis. 2016;3(4):ofw184.","journal-title":"Infect Dis."}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-022-02871-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-022-02871-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-022-02871-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T06:03:44Z","timestamp":1658988224000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-022-02871-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,28]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2871"],"URL":"https:\/\/doi.org\/10.1186\/s13075-022-02871-1","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,28]]},"assertion":[{"value":"29 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Institutional Review Board of Seoul National University Hospital (2002-057-1100). The requirement for informed consent was waived as the HIRA database was anonymized with strict confidentiality guidelines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"180"}}